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Background: Colorectal carcinoma (CRC) is one of the leading causes of cancer-related mortality worldwide.
MicroRNAs (miRNAs, miRs) play important roles in carcinogenesis. MiR-32 has been shown to be upregulated in
CRC. In this study, we identified the potential effects of miR-32 on some important biological properties of CRC
cells, and clarified the regulation of PTEN by miR-32.
Methods: The effect of miR-32 on PTEN expression was assessed in CRC cell lines with miR-32 mimics/inhibitor to
increase/decrease miR-32 expression. Furthermore, the roles of miR-32 in regulating CRC cells biological properties




-UTR) of PTEN combined
with miR-32 was verified by dual-luciferase reporter assay.
Results: Gain-of-function and loss-of-function studies showed that overexpression of miR-32 promoted SW480 cell
proliferation, migration, and invasion, reduced apoptosis, and resulted in downregulation of PTEN at a
posttranscriptional level. However, miR-32 knock-down inhibited these processes in HCT-116 cells and enhanced
the expression of PTEN protein. In addition, we further identified PTEN as the functional downstream target of
miR-32 by directly targeting the 3
0
-UTR of PTEN.
Conclusions: Our results demonstrated that miR-32 was involved in tumorigenesis of CRC at least in part by
suppression of PTEN.
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Colorectal carcinoma (CRC) is one of the most common
cancers, and is a significant contributor to cancer death
[1]. CRC carcinogenesis is a multi-step process in which
a normal cell undergoes malignant transformation to a
fully developed tumor through accumulations of genetic
and epigenetic changes. Although a number of molecu-
lar events have been identified, more and more new
molecules that play a role in this process remain to be* Correspondence: Venus.eon@163.com; ahdg2005@126.com
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reproduction in any medium, provided the ordiscovered, which are crucial for development of improved
therapeutic approaches. Thus, a deeper understanding of
the molecular and genetic networks that control the initi-
ation and progression of CRC is imperative.
MicroRNAs (miRNAs, miRs) are small non-coding
RNAs that regulate gene expression by the inhibition of
the translation and/or decreasing of the stability of target
mRNAs [2]. MicroRNAs participate in gene regulation,
apoptosis, hematopoietic development, the maintenance
of cell differentiation, and tumor genesis [3]. Recent data
suggest that dysregulation of miRNAs is an important step
in the pathogenesis, from initiation to metastasis, of many
cancers including CRC [4-6]. The dysregulation of miRNA
expression is associated with oncogenic transformation.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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miR-124 and miR-142-3p) [7-9] or oncogenes (e.g., miR-
21, miR-218, and miR-24) [10-12] have been identified in
many types of tumors. Strillacci et al. [13] reported an in-
verse correlation between COX-2 and miR-101 expression
in colon cancer cell lines, and demonstrated the direct
inhibition of COX-2 mRNA translation mediated by
miR-101. Shen et al. [14] found that miR-139 inhibits inva-
sion and metastasis of CRC by targeting the type I insulin-
like growth factor receptor. Recently, Sarver et al. [15]
using microarray analysis had shown that miR-32 was
upregulated in CRC. In their study, the authors quantified
the expression levels of 735 miRNAs in 80 human CRC
samples and 28 normal colon tissues, and identified 39
miRNAs, including miR-32, whose expression levels were
significantly altered in CRC samples. However, the func-
tion of miR-32 in CRC remains unknown.
The phosphatase and tensin homologue (PTEN) pro-
tein is a well-known anti-oncogene. PTEN is one of the
most frequently mutated tumor suppressors in a variety
of human cancers [16-18]. Its loss of expression is asso-
ciated with tumor progression and poor clinical outcome
in CRC [19]. Nuclear PTEN expression gradually de-
creases during the normal-adenoma-adenocarcinoma se-
quence, which suggests an important role for PTEN in
carcinogenesis [20]. PTEN is a negative regulator of the
PI3K/Akt pathway [21], and the PTEN loss-PI3K/pAkt
pathway may play an important role in sporadic colon
carcinogenesis. Reduction of PTEN expression may pre-
dict relapse in CRC patients [22]. Bioinformatics has
shown that the 30-UTR of PTEN contains a putative bind-
ing site for miR-32. However, the regulation of miR-32 in
CRC or it association with PTEN have not been reported.
In this study, we focused on the expression and function
of miR-32 in CRC cells. In gain-of-function and loss-of-
function studies, we found that miR-32 promoted CRC
cells growth, migration, invasion, and reduced apoptosis.
Overexpression of miR-32 resulted in downregulation of
PTEN at a posttranscriptional level. By using a luciferase-
reporter gene, we identified PTEN as the functional down-
stream target of miR-32.
Results
Expression of miR-32 in CRC cell lines
We first analyzed the expression level of miR-32 in a
panel of CRC cell lines with different degrees of differen-
tiation and metastatic ability including LOVO (undiffer-
entiated), HT-29 (high differentiation), HCT-116 (low
differentiation), SW480 (low metastatic ability), SW620
(high metastatic ability). We observed that miR-32 ex-
pression was relatively higher in HCT-116 cells than in
HT-29 cells, and also was lower in SW480 cells than in
SW620 cells (Figure 1), suggesting that miR-32 expres-
sion may be associated with the degree of CRC celldifferentiation and metastatic ability. Based on this
expression pattern, we therefore chose SW480 and
HCT-116 cells for the following gain-of-function and
loss-of-function studies, respectively.MiR-32 binds to the 30-UTR of PTEN
Analysis by using publicly available programs, TargetScan
(http://www.targetscan.org) and miRanda (http://www.
microrna.org), indicates that PTEN is theoretically the tar-
get gene of miR-32 (Figure 2A). We then performed a
luciferase reporter assay to verify that miR-32 directly tar-
gets PTEN. We found that co-transfection of miR-32
mimics and pmiR-PTEN-wt significantly decreased the lu-
ciferase activity in SW480 cells as compared with the con-
trol. However, miR-32 mimics had no effect on the
luciferase activity when co-transfected with pmiR-PTEN-
mut (Figure 2B). These data showed that PTEN is one of
direct targets of miR-32.Alteration of miR-32 expression changed PTEN protein
expression but not mRNA level
PTEN had been reported to regulate CRC carcinogenesis
[19]. To further confirm that PTEN was the downstream
target of miR-32, up-regulation and down-regulation of
miR-32 expression were conducted with subsequent de-
tection of PTEN mRNA and protein change. Compared to
miR-32 mimics-NC or blank control (without transfec-
tion), transfection with 100 nM of miR-32 mimics in
SW480 cells led to an approximately 300-fold increase in
miR-32 expression as detected by qRT-PCR (Figure 3A).
The increase in endogenous miR-32 levels significantly de-
creased PTEN protein expression as determined by west-
ern blot (P < 0.05) (Figure 3B, C), while mRNA remained
unchanged (P > 0.05) (Figure 3D). In contrast, to conduct
loss-of-function experiments 150 nM of miR-32 inhibitor
was transfected into HCT-116 cells and compared to miR-
32 inhibitor-NC or blank control. The results showed a
decrease of miR-32 expression (Figure 3A) and an increase
PTEN protein expression (P < 0.05) (Figure 3B, C) with no
mRNA alternation (P > 0.05) (Figure 3D).MiR-32 promoted CRC cell proliferation
MiR-32 has been reported to be upregulated in CRC by
miRNA microarray analysis [15], implicating its potential
role in CRC cells biological properties. To further
characterize the functional importance in CRC tumori-
genesis, we examined the effect of miR-32 on the prolif-
eration of CRC cells using MTT assay. We observed that
over-expression of miR-32 significantly promoted the
proliferation of SW480 cells, whereas miR-32 inhibition
restrained the proliferation of HCT-116 cells at 48, 72,






















Figure 1 qRT-PCR of miR-32 expression in CRC cell lines with different degrees of differentiation and metastasis ability. Data were the
means of three measurements and the bars represented SD of the mean.
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To measure the effect of miR-32 on CRC cell apoptosis,
72 h after transfection, apoptosis was measured at 72 h
after miR-32 transfection or miR-32 inhibitor treatment, by
flow cytometry. Annexin V-FITC(+) apoptotic cells were
significantly decreased in miR-32 mimics transfected group
compared to NC or blank control. The percentage ofA
Position 2859-2866 of PTEN-3’UTR 5’...AG



























Figure 2 MiR-32 and 30-UTR of PTEN. (A) Position of the miR-32 target s
32 on PTEN expression by luciferase reporter assay. SW480 cells were cotra
(or pmiR-PTEN-mut) vector. Luciferase activity was normalized by the ratio
fold change relative to the negative control.*P < 0.05 when compared to o
the bars represented SD of the mean.apoptotic cells in the miR-32 inhibitor treated group was
higher than he other two control groups (Figure 5). The
findings indicated the anti-apoptotic role in CRC cells.
MiR-32 promoted CRC cell migration and invasion
To evaluate the impact of miR-32 on cell migration and




ite in 30-UTR of PTEN mRNA predicted by TargetScan. (B) Effect of miR-
nsfected with miR-32 mimics(or miR-32 mimics-NC) with pmiR-PTEN-wt
of firefly and Renilla luciferase signals. The results were expressed as






























































































































































































Figure 3 (See legend on next page.)
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Figure 3 Alteration of miR-32 expression changes PTEN protein expression. (A) MiR-32 expression was detected by qRT-PCR. SW480 cells
transfected with miR-32 mimics showed an increase in miR-32 expression, while HCT-116 cells transfected with miR-32 inhibitor resulted in
significantly decreased miR-32 expression. *P < 0.05 when compared with corresponding negative control. (B) Representative pictures of PTEN
protein expression detected by western blot. (C) Quantitative analysis showed that PTEN protein expression in SW480 cells transfected with miR-
32 mimics decreased when compared with miR-32 mimics-NC or blank control. PTEN protein increased in miR-32 inhibitor transfected HCT-116
cells when compared with miR-32 inhibitor-NC or blank control. *P < 0.05 (D) Transfected cells had no alternation in PTEN mRNA level. Data were
the means of three measurements and the bars represented SD of the mean.
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miR-32 induced SW480 cell migration (Figure 6A),
whereas its knock-down inhibited HCT-116 cell migra-
tion (Figure 6B). Consistent with this finding, matrigel
invasion assay showed that miR-32 overexpression sig-
nificantly enhanced invasion capacity of SW480 cells
(Figure 7A), while knock-down of miR-32 inhibited inva-
sion in HCT-116 cells (Figure 7B). These observations
suggested that miR-32 played an important role in pro-
moting migration and invasive potential of CRC cells.
Discussion
Identification of cancer-specific miRNAs and their tar-
gets is critical for understanding their roles in tumori-
genesis, and may be important for finding out novel
therapeutic targets. The expression of miR-32 has been
shown to be upregulated in diverse types of malignan-
cies, e.g. kidney cancer and prostate cancer [23,24], and
recently miR-32 was shown to be androgen-regulated
and overexpressed in castration-resistant prostate cancer.
MiR-32 has also been demonstrated to reduce apoptosis by
targeting B-cell translocation gene 2 (BTG2), a transcrip-
tional cofactor that has antiproliferative properties [25].
Gocek et al. [26] also reported that miR-32 blockade was
sufficient to elevate proapoptotic factor Bim expression




























Figure 4 The viable cell number was evaluated as the value of the ab
SW480 cells proliferation and transfection with miR-32 inhibitor inhibited H
different time points. *P < 0.05, as compared miR-32 mimics or inhibitor wi
were the means of three measurements of OD and the bars represented Schemotherapy-induced apoptosis. These data underline a
fundamental role of this miRNA as an oncogene. Cur-
rently, there are accumulating evidences that the aberrant
expression of miRNAs is linked to the development of
CRC [15,27]. Using a miRNA microarray analysis, it has
been reported that miR-32 is significantly upregulated in
CRC [15]. However, the function of miR-32 in CRC car-
cinogenesis remains unknown.
In this study we investigated the function and possible
mechanisms of miR-32 in regulating some biological prop-
erties of CRC cells. First, we found that endogenous miR-
32 expression is relatively high in low-differentiated HCT-
116 cells and low in differentiated HT-29 cells. We also
found that its expression is lower in low metastatic ability
SW480 cells than in high metastatic ability SW620 cells.
This expression pattern raises that possibility that miR-32
is related to some CRC biological properties.
Based on the miR-32 expression level, we chose SW480
and HCT-116 cells for the subsequent gain-of-function
and loss-of-function studies, respectively. Our results sup-
ported that miR-32 promoted CRC cells growth, migra-
tion, and invasion and reduces apoptosis in vitro. On the
other hand, downregulation of miR-32 in CRC was related
to its inhibition. To address the molecular mechanisms in-
volved in miR-32-mediated biological properties change,


























sorbance at 570 nm. Transfection with miR-32 mimics promoted
CT-116 cells proliferation compared to the corresponding control at
th other two corresponding groups at the indicated time points. Data
D of the mean.
blank control            miR-32 mimics-NC          miR-32 mimics












































Figure 5 Apoptosis assay. (A) Percentage of apoptotic cells out of total measured cell population was seen in the bottom right quadrant. A
representative experiment of three performed was shown. (B) The results were expressed as fold change relative to the corresponding blank
control. *P < 0.05, as compared miR-32 mimics or inhibitor with other two corresponding groups. Data were the means of three measurements
and the bars represented SD of the mean.
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lysis. The PTEN gene has been identified as a tumor sup-
pressor gene located on human chromosome region 10q23
[28]. The key target of PTEN is phosphatidylinositol 3, 4,
5-trisphosphate (PIP3) [29], the direct product of phos-
phatidylinositol 3-kinase (PI3K). The PTEN/PI3K/Akt
pathway is highly involved in tumorigenesis. PTEN has
been shown to inhibit tumor cell growth and invasion by
blocking the PI3K/Akt pathway [30]; it can dephosphatizePI3K at the 3-phosphate site and negatively regulates the
Akt signal pathway. Akt regulates cell growth and inhibits
apoptosis via controlling downstream proteins [21]. Thus,
alteration of PTEN facilitates cell proliferation, invasion,
migration, and angiogenesis [31-33] and inhibits apoptosis
[34-36]. Loss of nuclear PTEN expression was found to be
associated with liver metastasis, and reduced PTEN expres-
sion predicts local recurrence in CRC [37]. PTEN expres-

































































Figure 6 (See legend on next page.)
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Figure 6 Wound healing assay. SW480 and HCT-116 cells were transfected with miR-32 mimics and miR-32 inhibitor, respectively. Movement of
cells into wound was shown for miR-32 mimics (A), and miR-32 inhibitor-transfected (B) cells at 0 and 36 h post scratch (40×). The arrows
indicated the boundary lines of scratch. Cell migration was assessed by recover of the scratch. The area of the wound was measured at the two
time points in every group, and % reduction of initial scratch area was compared. *P < 0.05, as compared miR-32 mimics or inhibitor with other
two corresponding groups. (C) The results were expressed as fold change relative to the corresponding blank control. Data were the means of
three measurements and the bars represented SD of the mean.
A
B
miR-32 mimics miR-32 mimics-NC blank control 









































Figure 7 Transwell invasion assay. SW480 and HCT-116 cells were transfected with miR-32 mimics and miR-32 inhibitor, respectively. (A, B)
CRC cells penetrating the membrane were fixed and 0.1% crystal violet stained after 24 h as described in experimental procedures. (C) CRC cells
penetrating the membrane were represented as the fold over blank control. *P < 0.05, as compared miR-32 mimics with its other two groups, or
miR-32 inhibitor with other two groups. Data were the means of three measurements and the bars represented SD of the mean.
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signal pathway [38]. Hence, it is an attractive target for
anti-cancer therapy.
Our study showed that PTEN was a possible target of
miR-32, and their antagonistic interaction may play a role
in the development of CRC. First, the luciferase reporter
assay demonstrated its downregulation was mediated by
the direct binding of miR-32 to the PTEN 30-UTR, be-
cause the alteration of this region abolished this effect.
Secondly, overexpression of miR-32 suppressed PTEN
protein levels without any change in PTEN mRNA expres-
sion, and vice versa. Therefore, we proposed that the main
mechanism of miR-32-induced PTEN suppression was
post-transcriptional. Finally, overexpression of miR-32 led
to increased cell proliferation, migration, invasion and re-
duced apoptosis in CRC cells.
Our results provided the first insight into the function
of miR-32 in regulating some biological properties of
CRC cells, at least in part by targeting the anti-oncogene
PTEN, highlighting the function of miRNA in the
process of tumor progression.
Conclusions
In conclusion, the present study demonstrated previ-
ously uncharacterized biological functions of miR-32 in
CRC cells In addition, PTEN was negatively regulated at
the posttranscriptional level by miR-32 via a binding site
of PTEN-30-UTR. These findings suggested that miR-32
was possibly involved in tumorigenesis of CRC at least
in part by suppression of PTEN. And miR-32 was a po-
tential candidate for miRNA-based therapy against CRC.
Material and methods
Cell culture and reagents
The CRC cell lines HT-29, HCT-116, LOVO, SW480, and
SW620 were cultured in RPMI-1640 medium (Gibco,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco, USA), 100 IU/ml penicillin and 100 μg/ml strepto-
mycin in humidified 5% CO2 at 37°C. MiR-32 mimics,
miR-32 mimics negative control (miR-32 mimics-NC),
miR-32 inhibitor, and miR-32 inhibitor negative control
(miR-32 inhibitor-NC) were purchased from Ribobio
(RiboBio Co. Ltd., China).
Real-time quantitative RT-PCR (qRT-PCR)
To quantitate miRNA expression, total RNA was extracted
from CRC cell lines with RNAiso Plus (Takara, Japan). The
isolated total RNA was reverse transcribed using the One
Step PrimeScriptW miRNA cDNA Synthesis Kit (Takara,
Japan) according to the manufacturer’s instructions. Rela-
tive expression was calculated via the comparative cycle
threshold (Ct) method using the expression of U6 small nu-
clear RNA as the reference. The sequence-specific forward
primers for mature miR-32 and U6 internal control were50- CGGTATTGCACATTACTAAGTTGCA -30 and 50-
CTCGCTTCGGCAGCACA-30, respectively. The Uni-miR
qPCR Primer was included in the kit. The amount
of miRNA was monitored with SYBR® Premix Ex Taq™ II
(Perfect Real Time) (Takara, Japan). The reactions were
performed on a LightCycler® (Roche Diagnostics, USA).
The PCR conditions were 30s at 95°C, followed by
40 cycles at 95°C for 5 s and 60°C for 20s. The
2-△Ct(2-[(Ct of gene) -(Ct of U6)]) method was used for analysis.
Cell transfection
The miR-32 gain-of-function study was performed using
miR-32 mimics (100 nM) and its negative control (100 nM)
on the SW480 cell line. The loss-of-function study was
performed with miR-32 inhibitor (150 nM) and its negative
control (150 nM) on the HCT-116 cell line. For each cell
line, there was a blank control without any transfection.
Cells were transfected using lipofectamine™ 2000 reagent
(Invitrogen, USA) in Opti-MEM (Gibco, USA), according
to the manufacturer’s instructions. The relative level of
miR-32 in transfected cells was examined by qRT-PCR.
Dual-luciferase reporter assay
The region of human PTEN-30UTR, generated by PCR
amplification, was cloned into the pmiR-RB-REPORT™ lu-
ciferase reporter plasmid (RiboBio Co. Ltd., China). The





TG -30, PTEN-30UTR-mut-R: 50-TGAACAATTAGGAG
CAAAATTTCTAGAACTAAACATT-30. These constructs
were named pmiR-PTEN-wt and pmiR-PTEN-mut. For the
reporter assay, SW480 cells were plated onto 24-well plates
and transfected with 500 ng of pmiR-PTEN-wt or pmiR-
PTEN-mut and 100 nM miR-32 mimics or NC using
lipofectamine 2000. After transfection for 48 h, cells were
harvested and assayed with the Dual-Luciferase Reporter
Assay System (Promega, USA) according to the manufac-
turer’s instructions. The tests were repeated in triplicate.
qRT-PCR for the miR-32 and PTEN mRNA
Transfected cells were incubated 48 h before RNA extrac-
tion. qRT-PCR for miR-32 after transfection was
performed as previously described. For PTEN, total RNA
was reverse transcribed using the PrimeScript® RT Master
Mix Perfect Real Time (Takara, Japan). PTEN mRNA level
was normalized to housekeeping gene β-actin with the fol-
lowing primers: PTEN forward 50- AAAGGGACGAAC
TGGTGTAATG -30, and reverse 50- TGGTCCTTACTT
CCCCATAGAA -30; β-actin forward 50- GGCGGCAAC
ACCATGTACCCT -30, and reverse 50-AGGGGCCG
Wu et al. Molecular Cancer 2013, 12:30 Page 10 of 11
http://www.molecular-cancer.com/content/12/1/30GACTCGTCATACT-30. Changes in the expression were
calculated using the 2-△Ct method.Western blot
Transfected cells were harvested for immunoblot ana-
lysis after 72 h incubation. Cells were lysed in lysis buffer
(Beyotime, China), and protein concentrations were
measured using the BCA protein assay kit (Beyotime,
China). Total protein was separated by SDS-PAGE using
a 12% polyacrylamide gel and electroblotted onto a
polyvinylidenefluoride membrane (PVDF; Millipore,
USA). The membrane was immunoblotted overnight at
4°C with primary antibodies: rabbit monoclonal antibody
against human PTEN (1:500 dilution; Cell Signaling
Technology, USA), mouse monoclonal antibody against
human β-actin (1:2000 dilution; Beyotime, China). A
secondary antibody, horseradish peroxidase-conjugated
goat IgG (1:1000 dilution; Beyotime, China), was incu-
bated with the membrane for 1 h after 3 washes with
TBST. Signals were detected with ECL detection reagent
(Beyotime, China). The images were obtained on Kodak
film and quantified by Quantity One (Bio-Rad, USA). All
experiments were performed in triplicate.MTT assay
Viable cell numbers were measured with 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. SW480 or HCT-116 cells were plated in
96-well plates and incubated for 24, 48, 72, 96 h respect-
ively after transfection. 20 μl of 5 mg/mL MTT (Sigma,
USA) was added into each corresponding test well, and
incubated for 4 h in 37°C incubator. The supernatant
was then discarded, and 200 μl of DMSO (dimethyl sulf-
oxide)was added to each well to dissolve the formazan.
Optical density (OD) was evaluated by measuring the
absorbance. The absorbance at 570 nm (A570) of each
well was read on a spectrophotometer. All experiments
were performed in triplicate.Apoptosis assay
The apoptosis ratio was analyzed using the Annexin
V-FITC Apoptosis Detection Kit (Beyotime, China). At
72 h after transfection cells were harvested and
resuspended in binding buffer containing Annexin
V-FITC and PI according to the manufacturer’s instruc-
tions. The samples were analyzed by flow cytometry
(FACScan; BD Biosciences, USA). Cells were discrimi-
nated into viable cells, necrotic cells, and apoptotic
cells by using BD FACSDiva 6.1.3 software (BD Biosci-
ences, USA), and then the percentages of apoptotic
cells from each group were compared. Tests were re-
peated in triplicate.Wound healing assay
SW480 cells or HCT-116 cells were seeded onto 6-well
plates. When the cell confluence reached about 80% and
above at around 48 h post-transfection, scratch wounds
were made by scraping the cell layer across each culture
plate using the tip of 10 μl pipette. After wounding, the
debris was removed by washing the cells with PBS.
Wounded cultures were incubated in serum-free
medium for 36 h, and then 3 fields (40×) were randomly
picked from each scratch wound and visualized by mi-
croscopy to assess cell migration ability. The experi-
ments were performed in triplicate.
In vitro transwell invasion assay
Transwell membranes (polycarbonic membrane, diameter
6.5 mm, pore size 8 μm) (Corning Costar, USA) coated
with Matrigel (BD Biosciences, USA) were used to assay
cell invasion in vitro. At 48 h post-transfection, cells were
resuspended into serum-free medium. Transfected cells
(10 × 104 in 200 μl serum-free medium) were reseeded
into the upper chamber, and 0.6 ml medium with 10%
FBS was added to the lower chamber as chemoattractant.
After 24 h incubation, non-invading cells on the upper
surface of the membrane were removed with a cotton
swab. The invasive cells, which penetrated to the lower
surface, were fixed with 4% paraformaldehyde and stained
with 0.1% crystal violet (Beyotime, China). The number of
cells invading the membrane was counted from 5 ran-
domly selected visual fields with an inverted microscope
at 100× magnification. Data were obtained from 3 inde-
pendent experiments.
Statistical analysis
Experimental data were presented as the mean ± standard
deviation (SD). All statistical analyses were performed
using T-test when only 2 groups were compared, and by
ANOVA when 3 or more groups were compared. All ana-
lyses were performed with SPSS 19.0 (SPSS Inc., USA),
and a value of P < 0.05 was considered to indicate statis-
tical significance.
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